Pre-Seed Biotech pitch decks that fund the next key experiment.
Pre-seed biotech is about funding a scientific thesis to its first meaningful proof point. The deck must make the target rationale and early data legible, show the IP position, and tie the capital to specific experiments that de-risk the program.
At a glance
- Typical deck length
- 10–14 slides
- Who you're pitching
- Angels, pre-seed and seed micro-funds, accelerators, and operator-investors writing the first institutional checks.
- Lead with
- Early data package · Target validation evidence · IP status




What Pre-Seed Biotech investors need to believe.
A Biotech round at Pre-Seed turns on a handful of beliefs. Your deck should build each one before a partner has to ask.
The biology is compelling
There's a clear target rationale with genetic, clinical or mechanistic support.
Early data points the right way
Initial in vitro or in vivo data is directionally convincing and reproducible.
IP can be protected
There's a credible path to composition-of-matter or method protection, or freedom to operate.
The money buys a real readout
The round funds experiments that produce a value-inflecting data package.
What to lead with at Pre-Seed.
At this stage, these are the numbers and evidence that carry the room. Each one should tie out to your model and data room.
Early data package
Show the key experiments with clear controls, kept to the figures that matter.
Target validation evidence
Summarize the genetic or clinical evidence linking the target to disease.
IP status
List filed or licensed patents and the freedom-to-operate position.
Experiment plan and budget
Map each experiment to cost, timeline and the decision it informs.
Round structure
State the instrument and amount so seed-stage specialists can engage quickly.
How to structure a Pre-Seed Biotech deck.
A 10–14 slides structure tuned for this round. Tap any slide for the full guide.
-
Title Slide
At pre-seed the one-liner carries extra weight: with little traction to show, it has to make the vision concrete and the category instantly clear.
-
Problem Slide
Frame the unmet need by patient population and the limits of current standard of care, not market size alone.
Biotech-specific -
Solution Slide
Explain mechanism of action in one clear diagram a generalist can follow and a specialist won't fault.
Biotech-specific -
Why Now Slide
At pre-seed, why-now is often the core of the thesis; a sharp timing argument can stand in for traction when investors are betting on a window.
-
Team Slide
At pre-seed, the team slide is often the deciding factor; lead with founder-market fit and the unique insight each founder brings to the problem.
-
Market Size Slide
At pre-seed, market sizing proves the bet is worth making; clear bottom-up logic matters more than precision, since investors are underwriting upside.
-
Product Slide
At pre-seed, a prototype, clickable mockup or short demo video is enough — just be clear about what's built and what's planned.
-
Traction Slide
At pre-seed, traction can be qualitative — discovery interviews, a waitlist, letters of intent or a pilot — anything that shows real demand before revenue.
-
Business Model Slide
At pre-seed, a clear hypothesis is enough: who pays, the intended pricing model and why customers will value it at that level.
-
Competition Slide
At pre-seed, focus on your insight and approach: why existing solutions miss the problem and why your angle is hard for them to copy.
-
The Ask & Use of Funds Slide
Tie the raise to the specific experiments and the data package they produce for a seed or Series A raise.
Biotech-specific
What Biotech investors will push on at Pre-Seed.
Is this reproducible outside the founder's lab?
How the deck answers it: Show replication, independent validation or a plan with a CRO to replicate key results early.
Who owns the IP — you or the university?
How the deck answers it: Clarify license terms, options and what's in place versus under negotiation.
Why is this target druggable?
How the deck answers it: Address modality choice and tractability head-on with data or precedent.
Trusted by founders. Backed by results.
They were able to give us insight into a comprehensive and emerging landscape. They provided further resources with case studies and data to make our arguments more compelling; while being timely and communicative. They're an asset to any team moving forward.
[They] were educated in the biopharma space and was able to give us insight into the landscape. They provided further resources/data to make our arguments more compelling. He was timely and communicative. An asset to any team moving forward.
(For our acquisition of Modular Water), they really built the case with deep research. Highly professional. They took the time to work through a number of iterations of the project and maintained outstanding communication. Highly recommend.
Common questions. Clear answers.
What data do I need for a pre-seed biotech raise?
Should a pre-seed biotech deck include market size?
What does a custom engagement cost?
How fast can you turn it around?
Keep exploring.
Raising your Pre-Seed round? Get the deck right first.
Drop your details and we'll send a free deck audit — then jump on a 15-minute intro call to walk through exactly what to fix before you pitch.
- We reply within 24 hours
- Complete founder confidentiality
Got it — your audit is on the way.
We'll review your details and reply within 24 hours. Want to fast-track it? Grab a 15-minute intro call now.
Book your intro call